Results 171 to 180 of about 4,655,222 (236)

Endovascular Stenting and Factor Xa Inhibitors for Filter-Associated Chronic IVC Occlusion: A Case Series. [PDF]

Am J Case Rep
Cao P, Luo X, Gao R, Li Y, Li L, Zhang Y, Liu X.   +6 more
europepmc   +1 more source

Adverse Events of Factor Xa Inhibitors in Pediatric Patients: A Meta-analysis and Pharmacovigilance Study. [PDF]

Paediatr Drugs
Chong S, Sun L, Mu G, Hua M, Xiang Q, Cui Y.   +5 more
europepmc   +1 more source

The Efficacy of Andexanet Alfa for the Reversal of Factor Xa Inhibitors Is Not Influenced by Hemodilution with Different Volume Expanders. [PDF]

J Clin Med
Wienhold J, Rossaint R, Vandeput E, Grottke O.   +3 more
europepmc   +1 more source

Effect of the frequently used antiepileptic drugs carbamazepine, gabapentin, and pregabalin on the pharmacokinetics of edoxaban and other oral factor xa inhibitors in healthy volunteers. [PDF]

Front Pharmacol
Lenard A, Hermann SA, Stoll F, Burhenne J, Foerster KI, Czock D, Mikus G, Meid AD, Haefeli WE, Blank A.   +9 more
europepmc   +1 more source

Safety and Efficacy of Oral Direct Factor Xa Inhibitors in Patients With Nephrotic Syndrome: Results From a National Retrospective Study. [PDF]

Kidney Int Rep
Arches C, Jalal-Eddine A, Titeca-Beauport D, Dao M, Lobbedez T, Zaoui P, Masset C, Bertrand D, El Karoui K, Brenier H, Sakhi H, Peiffer B, Audard V, Joher N.   +13 more
europepmc   +1 more source

The impact of factor Xa inhibitors on bleeding risk in patients with respiratory diseases. [PDF]

Sci Rep
Hamada S, Muramoto K, Akaike K, Okabayashi H, Masunaga A, Tomita Y, Ichiyasu H, Sakagami T.   +7 more
europepmc   +1 more source

Development of a Medication-Use Evaluation Template for Andexanet Alfa in the Reversal of Anticoagulation With Factor Xa Inhibitors. [PDF]

J Pharm Pract
Fera T, Burnett A, Grandoni J, Moore MR, Nussbaum BB, Pollack CV, Rose AE, Spinler SA, Streiff MB, Turck CJ, Fanikos J.   +10 more
europepmc   +1 more source

Venous thromboembolism treatment failure during use of factor Xa inhibitors-association with thoracic outlet syndrome and development of chronic thromboembolic pulmonary hypertension. [PDF]

Ann Med
Kaksonen M, Simonen P, Lassila R, Pentikäinen M.   +3 more
europepmc   +1 more source

Incidence and Predictors of Clinical Outcomes in Real-Life Patients With Atrial Fibrillation Treated With Oral Factor Xa Inhibitors: The Follow-Up Results of the ANATOLIA-AF Study. [PDF]

Clin Cardiol
Kocabaş U, Ergin I, Sönmez SC, Yavuz V, Murat S, Özdemir IH, Genç Ö, Tüner H, Meriç BK, Aslan O, Dal A, Taşkın U, Şen T, İbişoğlu E, Erdoğan A, Özgeyik M, Demir M, Urgun ÖD, Doğduş M, Çakal S, Çayırlı S, Güler A, Karabulut D, Dalgıç O, Murat B, Karabulut U, Öztekin GMY, Biter Hİ, Sinan ÜY, Barış VÖ, Kaplan M, Altın C, Kıvrak T.   +32 more
europepmc   +1 more source

Heavy menstrual bleeding on direct factor Xa inhibitors: the MEDEA randomized clinical trial. [PDF]

Res Pract Thromb Haemost
Hamulyák EN, Wiegers HMG, Hutten BA, de Lange ME, Timmermans A, Westerweel PE, Nijziel MR, Klok FA, Hovens MM, Kamphuisen PW, Büller HR, Middeldorp S, Scheres LJJ.   +12 more
europepmc   +1 more source